These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 21854301)

  • 1. Taribavirin in the treatment of hepatitis C.
    Deming P; Arora S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1435-43. PubMed ID: 21854301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribavirin analogs.
    Shields WW; Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):419-27. PubMed ID: 19628158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taribavirin for the treatment of chronic hepatitis C.
    Kearney KR; Thornton JJ; Navarro VJ
    Expert Opin Pharmacother; 2008 Dec; 9(18):3243-9. PubMed ID: 19040344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM; Heil EL
    Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of a new phosphorylated ribavirin prodrug.
    Dong SD; Lin CC; Schroeder M
    Antiviral Res; 2013 Jul; 99(1):18-26. PubMed ID: 23624267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin.
    Watson J
    Curr Opin Investig Drugs; 2002 May; 3(5):680-3. PubMed ID: 12090539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.
    Missale G; Pilli M; Zerbini A; Penna A; Ravanetti L; Barili V; Orlandini A; Molinari A; Fasano M; Santantonio T; Ferrari C
    Gut; 2012 Jul; 61(7):1076-84. PubMed ID: 22337949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.
    Wu JZ; Larson G; Hong Z
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4006-8. PubMed ID: 15388466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
    Lin CC; Philips L; Xu C; Yeh LT
    J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The next step for taribavirin.
    Kwo PY; Vinayek R
    Hepatology; 2010 Oct; 52(4):1185-8. PubMed ID: 20879028
    [No Abstract]   [Full Text] [Related]  

  • 12. A new tool to study ribavirin-induced haemolysis.
    Brochot E; François C; Castelain S; Helle F; Van Nhien AN; Duchaussoy I; Capron D; Nguyen-Khac E; Duverlie G
    Antivir Ther; 2012; 17(7):1311-7. PubMed ID: 22951364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia.
    Shire NJ; Horn PS; Rouster SD; Stanford S; Eyster ME; Sherman KE;
    Hepatology; 2006 Nov; 44(5):1146-57. PubMed ID: 17058240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
    Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
    Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus.
    Buckwold VE
    J Antimicrob Chemother; 2004 Mar; 53(3):413-4. PubMed ID: 14963071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection.
    Aora S; Xu C; Teng A; Peterson J; Yeh LT; Gish R; Lau D; Rossi S; Lin CC
    J Clin Pharmacol; 2005 Mar; 45(3):275-85. PubMed ID: 15703363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
    Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
    Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.